Trials / Recruiting
RecruitingNCT07214779
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 466 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB123667 | Oral; tablet |
| DRUG | Investigator's choice of chemotherapy | The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol: |
Timeline
- Start date
- 2025-12-09
- Primary completion
- 2028-11-15
- Completion
- 2029-05-14
- First posted
- 2025-10-09
- Last updated
- 2026-04-16
Locations
155 sites across 15 countries: United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Japan, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07214779. Inclusion in this directory is not an endorsement.